KR100618922B1 - 치환된이소퀴놀린-3-카복스아미드,이의제조방법및이를포함하는약제학적조성물 - Google Patents

치환된이소퀴놀린-3-카복스아미드,이의제조방법및이를포함하는약제학적조성물 Download PDF

Info

Publication number
KR100618922B1
KR100618922B1 KR1019980043578A KR19980043578A KR100618922B1 KR 100618922 B1 KR100618922 B1 KR 100618922B1 KR 1019980043578 A KR1019980043578 A KR 1019980043578A KR 19980043578 A KR19980043578 A KR 19980043578A KR 100618922 B1 KR100618922 B1 KR 100618922B1
Authority
KR
South Korea
Prior art keywords
hydrogen
formula
chlorine
compound
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019980043578A
Other languages
English (en)
Korean (ko)
Other versions
KR19990037182A (ko
Inventor
클라우스 바이드만
카알-하인쯔 바링하우스
게오르그 챤크
울리히 베르너
Original Assignee
아베가 파텐트마나게멘트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아베가 파텐트마나게멘트 게엠베하 filed Critical 아베가 파텐트마나게멘트 게엠베하
Publication of KR19990037182A publication Critical patent/KR19990037182A/ko
Application granted granted Critical
Publication of KR100618922B1 publication Critical patent/KR100618922B1/ko
Assigned to 피브로겐, 인크. reassignment 피브로겐, 인크. 권리의 전부이전등록 Assignors: 아베가 파텐트마나게멘트 게엠베하
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
KR1019980043578A 1997-10-20 1998-10-19 치환된이소퀴놀린-3-카복스아미드,이의제조방법및이를포함하는약제학적조성물 Expired - Lifetime KR100618922B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19746287A DE19746287A1 (de) 1997-10-20 1997-10-20 Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19746287.1 1997-10-20

Publications (2)

Publication Number Publication Date
KR19990037182A KR19990037182A (ko) 1999-05-25
KR100618922B1 true KR100618922B1 (ko) 2007-04-25

Family

ID=7846053

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019980043578A Expired - Lifetime KR100618922B1 (ko) 1997-10-20 1998-10-19 치환된이소퀴놀린-3-카복스아미드,이의제조방법및이를포함하는약제학적조성물

Country Status (24)

Country Link
US (1) US6093730A (https=)
EP (2) EP0911340B1 (https=)
JP (2) JP3782591B2 (https=)
KR (1) KR100618922B1 (https=)
CN (1) CN1117079C (https=)
AR (1) AR013696A1 (https=)
AT (2) ATE432940T1 (https=)
AU (1) AU755714B2 (https=)
BR (1) BR9804504B1 (https=)
CA (2) CA2250664A1 (https=)
CZ (1) CZ337298A3 (https=)
DE (3) DE19746287A1 (https=)
DK (2) DK1538160T3 (https=)
ES (2) ES2245471T3 (https=)
HU (1) HUP9802422A3 (https=)
ID (1) ID21115A (https=)
IL (1) IL126638A0 (https=)
NO (1) NO312365B1 (https=)
NZ (1) NZ332363A (https=)
PL (1) PL192354B1 (https=)
PT (1) PT911340E (https=)
SG (1) SG87776A1 (https=)
TR (1) TR199802106A2 (https=)
ZA (1) ZA989505B (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001275014A1 (en) * 2000-05-30 2001-12-11 Neurogen Corporation Imidazoloisoquinolines
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
DK2298301T3 (en) * 2001-12-06 2018-10-01 Fibrogen Inc MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
EP2295060B1 (en) 2001-12-06 2018-10-31 Fibrogen, Inc. Treatment or prevention of ischemic or hypoxic conditions
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US20060251638A1 (en) * 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
WO2004108681A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
AU2006254897A1 (en) * 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
MX2007016160A (es) 2005-06-15 2008-03-07 Fibrogen Inc Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer.
EP1960363B1 (en) 2005-12-09 2014-01-22 Amgen, Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions and uses thereof
BRPI0707302B8 (pt) 2006-01-27 2021-05-25 Fibrogen Inc compostos de cianoisoquinolina que atuam no dano tecidual associado com isquemia, hipóxia e anemia, bem como composição farmacêutica que os compreende
US7625927B2 (en) 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
KR100949975B1 (ko) * 2006-03-30 2010-03-29 엘지전자 주식회사 비디오 신호를 디코딩/인코딩하기 위한 방법 및 장치
BRPI0710527B8 (pt) 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
PL3357911T3 (pl) 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
AU2007334323B2 (en) 2006-12-18 2011-03-10 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
ES2393326T3 (es) 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
ES2446418T3 (es) 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
US8048894B2 (en) 2007-04-18 2011-11-01 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
EP2155746A2 (en) 2007-05-04 2010-02-24 Amgen, Inc Diazaquinolones that inhibit prolyl hydroxylase activity
US8962530B2 (en) * 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
CN101497584B (zh) * 2008-01-29 2010-12-22 首都医科大学 异喹啉-3-甲酰氨基酸苄酯及其制备和应用
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
EP3594213A1 (en) * 2009-07-17 2020-01-15 Japan Tobacco Inc. Triazolopyridine compounds and action thereof as prolyl hydroxylase inhibitors and erythropoietin production inducers
NO2686520T3 (https=) 2011-06-06 2018-03-17
CN104024227B8 (zh) * 2011-07-22 2025-07-29 北京贝美拓新药研发有限公司 抑制脯氨酸羟化酶活性的化合物的晶型及其应用
WO2013063221A1 (en) 2011-10-25 2013-05-02 Janssen Pharmaceutica Nv Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
WO2013134660A1 (en) 2012-03-09 2013-09-12 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
AU2013290438C1 (en) 2012-07-16 2019-01-03 Kyntra Bio, Inc. Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
EP3219706A1 (en) * 2012-07-16 2017-09-20 Fibrogen, Inc. Process for making isoquinoline compounds
WO2014070859A1 (en) 2012-10-30 2014-05-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stat3 dimerization inhibitors
AU2014209319B2 (en) 2013-01-24 2018-04-19 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
HRP20200615T1 (hr) 2013-06-06 2020-07-10 Fibrogen, Inc. Farmaceutske formulacije inhibitora hif hidroksilaze
JP2016521747A (ja) 2013-06-13 2016-07-25 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 貧血治療のための組成物及び方法
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
LT3466432T (lt) 2014-05-15 2020-12-28 Insmed Incorporated Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
EP4667059A3 (en) * 2015-05-28 2026-04-08 Japan Tobacco Inc. Method for treating or preventing diabetic nephropathy
US20180200186A1 (en) * 2015-07-09 2018-07-19 Insmed Incorporated Compositions and methods for treating lung diseases and lung injury
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
JP2021510175A (ja) * 2018-01-09 2021-04-15 コーネル ユニヴァーシティー 臓器線維症の予防と治療
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
JP7449275B2 (ja) 2018-05-02 2024-03-13 インスメッド インコーポレイテッド リポソーム薬物製剤の製造方法
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
WO2020028745A1 (en) * 2018-08-03 2020-02-06 Cornell University Methods for reducing abnormal scar formation
TWI865563B (zh) 2019-07-30 2024-12-11 德商拜耳動物保健有限公司 新穎異喹啉衍生物
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021117767A1 (ja) 2019-12-10 2021-06-17 田辺三菱製薬株式会社 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法
CN112979541B (zh) * 2019-12-17 2022-11-11 浙江大学 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用
CN116120340B (zh) * 2021-11-15 2023-10-31 艾立康药业股份有限公司 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950014072A (ko) * 1993-11-02 1995-06-15 엥겔하르트, 피셔 치환된 헤테로사이클릭 카복스아미드, 이의 제조방법 및 약제로서의 이의 용도
KR950017970A (ko) * 1993-12-30 1995-07-22 짜우너, 루츠 치환된 헤테로사이클릭 카복스아미드, 이의 제조방법 및 약제로서의 이의 용도
EP0765871A1 (de) * 1995-09-28 1997-04-02 Hoechst Aktiengesellschaft Substituierte Chinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Prolyl-4-hydroylase Inhibitoren
KR970701546A (ko) * 1994-03-10 1997-04-12 퀴놀린-3-카르복사미드 화합물의 새로운 용도(new use of quinoline-3-carboxamide compounds)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015255A1 (de) * 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
EP0548883A1 (de) * 1991-12-24 1993-06-30 Hoechst Aktiengesellschaft Substituierte Pyridin-N-oxide, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4233124A1 (de) * 1992-10-02 1994-04-07 Hoechst Ag Acylsulfonamido- und Sulfonamidopyridin-2-carbonsäureester sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ATE149485T1 (de) * 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950014072A (ko) * 1993-11-02 1995-06-15 엥겔하르트, 피셔 치환된 헤테로사이클릭 카복스아미드, 이의 제조방법 및 약제로서의 이의 용도
KR950017970A (ko) * 1993-12-30 1995-07-22 짜우너, 루츠 치환된 헤테로사이클릭 카복스아미드, 이의 제조방법 및 약제로서의 이의 용도
KR970701546A (ko) * 1994-03-10 1997-04-12 퀴놀린-3-카르복사미드 화합물의 새로운 용도(new use of quinoline-3-carboxamide compounds)
EP0765871A1 (de) * 1995-09-28 1997-04-02 Hoechst Aktiengesellschaft Substituierte Chinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Prolyl-4-hydroylase Inhibitoren

Also Published As

Publication number Publication date
AU8941398A (en) 1999-05-06
ID21115A (id) 1999-04-22
DK1538160T3 (da) 2009-10-05
TR199802106A3 (tr) 1999-05-21
NZ332363A (en) 2000-04-28
TR199802106A2 (xx) 1999-05-21
JP3782591B2 (ja) 2006-06-07
KR19990037182A (ko) 1999-05-25
ATE299148T1 (de) 2005-07-15
ZA989505B (en) 1999-04-20
DE59812907D1 (de) 2005-08-11
JPH11302257A (ja) 1999-11-02
US6093730A (en) 2000-07-25
ES2245471T3 (es) 2006-01-01
EP1538160B1 (de) 2009-06-03
HUP9802422A2 (hu) 1999-08-30
ATE432940T1 (de) 2009-06-15
EP1538160A1 (de) 2005-06-08
HU9802422D0 (en) 1998-12-28
CA2250664A1 (en) 1999-04-20
BR9804504B1 (pt) 2009-01-13
NO984877L (no) 1999-04-21
DE59814365D1 (de) 2009-07-16
CZ337298A3 (cs) 1999-05-12
DE19746287A1 (de) 1999-04-22
IL126638A0 (en) 1999-08-17
NO312365B1 (no) 2002-04-29
AU755714B2 (en) 2002-12-19
JP2006056894A (ja) 2006-03-02
EP0911340A3 (de) 1999-07-07
ES2328156T3 (es) 2009-11-10
EP0911340B1 (de) 2005-07-06
HK1019605A1 (en) 2000-02-18
EP0911340A2 (de) 1999-04-28
CA2251647C (en) 2011-08-30
JP4691419B2 (ja) 2011-06-01
CA2251647A1 (en) 1999-04-20
DK0911340T3 (da) 2005-11-07
BR9804504A (pt) 2001-05-22
PL329274A1 (en) 1999-04-26
CN1218802A (zh) 1999-06-09
NO984877D0 (no) 1998-10-19
PL192354B1 (pl) 2006-10-31
AR013696A1 (es) 2001-01-10
CN1117079C (zh) 2003-08-06
HUP9802422A3 (en) 2002-02-28
PT911340E (pt) 2005-09-30
SG87776A1 (en) 2002-04-16

Similar Documents

Publication Publication Date Title
KR100618922B1 (ko) 치환된이소퀴놀린-3-카복스아미드,이의제조방법및이를포함하는약제학적조성물
TW541316B (en) Prodrugs of thrombin inhibitors
US4294832A (en) Tetrahydroisoquinoline compounds and a pharmaceutical composition thereof
KR880002707B1 (ko) 우레아 유도체의 제조방법
KR20000065090A (ko) 3-알콕시피리딘-2-카복실산아미드에스테르,이의제조방법및약제로서의이의용도
KR19980063725A (ko) 3-하이드록시피리딘-2-카복스아미도에스테르, 이의 제조방법및 약제로서의 이의 용도
EP0480071A1 (en) S-(lower fatty acid)-substituted glutathione derivative
EP1055683A1 (en) Novel acetamide derivative and use thereof
WO1992018488A1 (en) Novel oxazinone derivative
PT100148B (pt) Processo para a preparacao de novos derivados dipeptidicos, contendo um anel piridinas
EP0178845A2 (en) Peptide-substituted heterocyclic immunostimulants
SK322003A3 (en) Thrombin inhibitors comprising an aminoisoquinoline group
US4678800A (en) Gamma-r-glutamoyl derivatives
US5166154A (en) Imidazo[1,2-a]piperazines
EP0059966B1 (en) Substituted thiazolidine carboxylic acid analogs and derivatives as antihypertensives
KR960008242B1 (ko) 벤조옥사디논유도체
MXPA98008644A (en) Amques of substitute isoquinolin-3-carboxylic acid, its preparation and its employment as a medicine
JPS633000A (ja) ペプチド誘導体類及びそれらの製造方法
US4711882A (en) Octahydro-6-azaindole compounds, compositions and use
JP2002522060A (ja) エキソケリンを合成するための新規方法
JPH07304744A (ja) 新規イソキノリン誘導体及びその酸付加塩
JPS6039263B2 (ja) （２Ｓ，３Ｒ）−３−アミノ−２−ヒドロキシ−４−ｐ−ヒドロキシフエニル酪酸
JPH08165293A (ja) 置換チアゾロ［３，２−ａ］アゼピン誘導体

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19981019

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20021120

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20031018

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19981019

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050713

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060125

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20060529

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20060825

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20060828

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

Publication date: 20070625

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

Publication date: 20070703

PR1001 Payment of annual fee

Payment date: 20090709

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20100811

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20111124

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20121122

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20121122

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20130820

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20130820

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20140811

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20150729

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20150729

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20160727

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20160727

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20170804

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20170804

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20180730

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20180730

Start annual number: 13

End annual number: 13

PC1801 Expiration of term